Julian Harrison
Stock Analyst at BTIG
(4.24)
# 437
Out of 5,090 analysts
69
Total ratings
56.45%
Success rate
15.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $5 | $1.56 | +221.54% | 3 | Dec 2, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $25 → $40 | $18.72 | +113.68% | 3 | Nov 26, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $32 → $38 | $10.57 | +259.51% | 2 | Nov 24, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $17 | $9.78 | +73.82% | 4 | Nov 20, 2025 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $42 → $44 | $6.98 | +530.37% | 2 | Nov 14, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $56 → $63 | $30.95 | +103.55% | 3 | Nov 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.51 | +298.41% | 2 | Nov 13, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $34.56 | +41.78% | 4 | Nov 4, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $61 | $32.07 | +90.21% | 4 | Nov 4, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $82 | $88.30 | -7.13% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.72 | +366.47% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.24 | +253.77% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $76.06 | +51.20% | 2 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.90 | +101.44% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $120 | $110.97 | +8.14% | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 | $14.97 | +467.80% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.67 | +126.37% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $57.50 | +73.91% | 1 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $33.45 | +109.30% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $41.56 | -10.97% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.64 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $44.19 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $1.96 | +360.36% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $2.96 | +170.27% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.38 | +2,032.20% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.77 | +19,443.08% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $484.82 | - | 2 | Feb 11, 2022 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.56
Upside: +221.54%
Theravance Biopharma
Nov 26, 2025
Maintains: Buy
Price Target: $25 → $40
Current: $18.72
Upside: +113.68%
Cullinan Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $10.57
Upside: +259.51%
Rezolute
Nov 20, 2025
Reiterates: Buy
Price Target: $17
Current: $9.78
Upside: +73.82%
Cartesian Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.98
Upside: +530.37%
Oruka Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $56 → $63
Current: $30.95
Upside: +103.55%
Connect Biopharma Holdings
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.51
Upside: +298.41%
Liquidia
Nov 4, 2025
Reiterates: Buy
Price Target: $49
Current: $34.56
Upside: +41.78%
Viridian Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $32.07
Upside: +90.21%
Protagonist Therapeutics
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $88.30
Upside: -7.13%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $1.72
Upside: +366.47%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.24
Upside: +253.77%
Oct 9, 2025
Reiterates: Buy
Price Target: $115
Current: $76.06
Upside: +51.20%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $13.90
Upside: +101.44%
Oct 7, 2025
Maintains: Buy
Price Target: $112 → $120
Current: $110.97
Upside: +8.14%
Sep 29, 2025
Downgrades: Neutral
Price Target: $85
Current: $14.97
Upside: +467.80%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.67
Upside: +126.37%
Sep 19, 2025
Reiterates: Buy
Price Target: $100
Current: $57.50
Upside: +73.91%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $33.45
Upside: +109.30%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $41.56
Upside: -10.97%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $21.64
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $44.19
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.96
Upside: +360.36%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.96
Upside: +170.27%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.38
Upside: +2,032.20%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.77
Upside: +19,443.08%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $484.82
Upside: -